The best option for smokers concerned about their health is to quit tobacco and nicotine use altogether. Our portfolio of smoke-free products is designed for smokers who would otherwise continue to smoke. For these smokers, the primary aim is to reduce their risk of developing smoking-related diseases compared with what it would be if they continued smoking.
However, smoke-free products are not risk-free and they contain nicotine, which is addictive. In order to identify the extent of reduction in risk compared to continued smoking, we are evaluating the risk profile of all our smoke-free products using a robust scientific assessment program. All of our platforms are at different stages of this assessment program.
Platform 1 is the most advanced in terms of scientific assessment. Starting with the aerosol, we have shown that by eliminating combustion, the levels of HPHCs are reduced on average by 95% compared to those measured in the smoke of a standard reference cigarette (3R4F) designed for research purposes.
We have also conducted regulatory toxicological assessment of the aerosol from Platform 1. Toxicity is a measurement of the degree of biological damage that a chemical or mixture of chemicals causes. This may or may not result in the development of disease. We have shown that in a laboratory setting, there is, on average, a 90-95% reduction in toxicity of the aerosol of Platform 1 compared to smoke from the 3R4F reference cigarette.